<DOC>
	<DOCNO>NCT02664558</DOCNO>
	<brief_summary>Ubenimex develop treatment pulmonary arterial hypertension ( PAH ) ( World Health Organization [ WHO ] Group 1 ) improve exercise capacity delay clinical worsening . This proof-of-concept study design Phase 2 , multicenter , randomize , double-blind , placebo control study compare ubenimex placebo patient PAH ( WHO Group 1 ) WHO/New York Heart Association ( NYHA ) Functional Classification ( WHO/NYHA-FC ) II III . The Primary Objectives study : - To evaluate efficacy ubenimex patient PAH ( WHO Group 1 ) . - To evaluate safety tolerability ubenimex patient WHO Group 1 PAH .</brief_summary>
	<brief_title>A Study Ubenimex Patients With Pulmonary Arterial Hypertension ( WHO Group 1 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Ubenimex</mesh_term>
	<criteria>1 . Male female , 1875 year old . 2 . Has diagnosis WHO Group 1 PAH . 3 . Right heart catheterization perform Screening result : 1 . Mean pulmonary arterial pressure ≥25 mmHg ( rest ) 2 . Pulmonary venous hypertension ( measure pulmonary capillary wedge pressure ( PCWP ) ≤15 mmHg . If PCWP available , mean leave atrial pressure leave ventricular enddiastolic pressure ≤15 mmHg absence leave atrial obstruction . 3 . Pulmonary vascular resistance ( PVR ) ≥300 dyn•s/cm5 ( 3.75 Wood unit ) 4 . Has WHO/NYHAFC II III . 5 . Be stable dose least one follow PAHspecific therapy : endothelin receptor antagonist , agent act nitric oxide pathway ( phosphodiesterase type 5 inhibitor soluble guanylate cyclase stimulator ) , and/or prostacyclin prostacyclin analog . 6 . Has 6minute walk distance ≥150 ≤500 meter . 7 . Have ventilationperfusion scan rule thromboembolic disease . Exclusions Related Cardiovascular Disease 1 . History uncontrolled hypertension 2 . Persistent hypotension Screening . 3 . Evidence history leftsided heart disease and/or clinically significant cardiac disease pulmonary hypertension likely WHO Group 2 . 4 . Acute decompensated heart failure within 1 month Screening . 5 . Recent initiation ( &lt; 8 week Screening ) plan initiation cardiopulmonary rehabilitation exercise program . Exclusions Related Pulmonary Disease 6 . Newly diagnose PAH PAHspecific therapy . 7 . Pulmonary hypertension due : 1 . Uncorrected congenital systemictopulmonary shunt . 2 . Pulmonary venoocclusive disease and/or pulmonary capillary hemangiomatosis 3 . Persistent pulmonary hypertension newborn 4. WHO clinical classification Groups 25 8 . Evidence significant airway and/or parenchymal lung disease . 9 . Chronic infection relate tuberculosis fungal mycobacterial disease . Exclusions Based Other Medical Conditions 10 . Chronic infection include , limited tuberculosis ( TB ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 11 . History portal hypertension chronic liver disease , include positive serology infection HCV and/or HBV . 12 . Evidence active infection require intravenous oral antibiotic within 4 week Screening . 13 . Body mass index ≥35.0 Screening . 14 . History obstructive sleep apnea . 15 . History malignancy within last 5 year , except nonmelanoma skin cancer cervical carcinoma situ treat curative intent . 16 . Neuropsychiatric disorders/symptoms psychological condition . 17 . Pregnancy breastfeed 18 . Prior treatment B cell lymphocytedepleting agent ( eg , rituximab , Campath ) Exclusions Based Concomitant Medication Use 19 . Concurrent regular use another leukotriene pathway inhibitor , include overthecounter medication herbal remedy . Exclusions Based Laboratory Values 20 . Significant/chronic renal insufficiency . 21 . Transaminases ( alanine transaminase , aspartate transaminase ) level &gt; 3 × upper limit normal ( ULN ) and/or bilirubin level &gt; 2 × ULN . 22 . Absolute neutrophil count &lt; 1500 mm3 . 23 . Hemoglobin concentration &lt; 9 g/dL Screening . 24 . Hepatic dysfunction define ChildPugh Class B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>